Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review

详细信息    查看全文

• 作者：Stephanie G.C. Kroeze^a ; ^{Stephanie.kroeze@usz.ch} ; Corinna Fritz^a ; Morten Hoyer^b ; Simon S. Lo^c ; Umberto Ricardi^d ; Arjun Sahgal^e ; Rolf Stahel^f ; Roger Stupp^f ; Matthias Guckenberger^a
• 关键词：Stereotactic radiotherapy ; Targeted therapy ; Concurrent ; Immunotherapy ; Toxicity
• 刊名：Cancer Treatment Reviews
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：53
• 期：Complete
• 页码：25-37
• 全文大小：1099 K
• 卷排序：53

文摘

Cranial SRT is well tolerated when combined with the majority of immuno- or targeted therapies. Cranial SRT concurrent with BRAF-Inhibitors should be performed with caution due to a risk of cerebral oedema and haemorrhage. Data on extra-cranial SRT is limited and needs separate evaluation of all drug and target site combinations. Risk of toxicity is increased after extra-cranial SRT combined with bevacizumab, sorafenib, cetuximab or EGFRi.